The Nasdaq logo displayed on a large outdoor screen. Source: Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Morgan Stanley and Jefferies are among the managers overseeing Telix Pharma’s (ASX:TLX) freshly commenced US IPO process to raise $300M and list on the NASDAQ.

First announced in mid-late May, Telix will offer American Depositary Shares (ADS) on the tech-heavy bourse that sports NVIDIA, Apple and Microsoft as its crown jewels.

Each ADS will represent one ordinary share in Telix.

The underwriters of the deal have an option to acquire up to 15% of the total ADS offering, which includes Morgan Stanley, Jefferies, and two other firms.

Morgan Stanley, if it is isn’t obvious, are a pretty good mob to have around for such a thing – it’s not like they haven’t got clients who’ll be interested.

The move comes at a fortuitous time for Telix Pharmaceuticals. The company’s stock price has been the beneficiary of recent test results the market liked.

At the same time, by looking at US IPO activity, it’s clear the biotech sector broadly is having a rebound in 2024 (which I also mean to include healthcare.)

Jefferies – another investment bank underwriting Telix’s IPO – are reasonably bullish on biotech.

According to their analysts, 2024 is the best environment biotech companies have been in since early COVID, with investment coming back to the notoriously risk-on sector.

The $5.97B market cap Telix is up +14% over the last week; up +17% over the last month, and, up +63% YoY.

TLX last traded at $17.89/sh.

TLX by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…